[go: up one dir, main page]

SG11201603506PA - Treatment of damaged nerve with pten inhibitor - Google Patents

Treatment of damaged nerve with pten inhibitor

Info

Publication number
SG11201603506PA
SG11201603506PA SG11201603506PA SG11201603506PA SG11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA
Authority
SG
Singapore
Prior art keywords
treatment
damaged nerve
pten inhibitor
pten
inhibitor
Prior art date
Application number
SG11201603506PA
Inventor
Kwan Hee Lee
Moon Jong Noh
Kwangwood Ahn
Original Assignee
Tissuegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissuegene Inc filed Critical Tissuegene Inc
Publication of SG11201603506PA publication Critical patent/SG11201603506PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0619Neurons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/13Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
SG11201603506PA 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor SG11201603506PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899795P 2013-11-04 2013-11-04
PCT/US2014/063900 WO2015066701A1 (en) 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor

Publications (1)

Publication Number Publication Date
SG11201603506PA true SG11201603506PA (en) 2016-05-30

Family

ID=53005300

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603506PA SG11201603506PA (en) 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor

Country Status (9)

Country Link
US (2) US10584153B2 (en)
EP (1) EP3066116B1 (en)
JP (1) JP6483115B2 (en)
KR (2) KR102086886B1 (en)
CN (1) CN105873942B (en)
AU (1) AU2014341899B2 (en)
CA (1) CA2929483C (en)
SG (1) SG11201603506PA (en)
WO (1) WO2015066701A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049994B (en) * 2016-12-08 2023-05-02 拜西欧斯(北京)生物技术有限公司 A kind of conjugate and its application
EP3773506A4 (en) * 2018-03-29 2021-12-22 Technion Research & Development Foundation Limited BUBBLES WITH A PTEN INHIBITOR AND USES
KR20200080554A (en) * 2018-12-27 2020-07-07 가톨릭관동대학교산학협력단 Composition comprising ebp50 for peripheral nerve repair
JP2024504869A (en) * 2020-12-04 2024-02-01 コロン ティッシュジーン,インク Treatment of spinal cord injury with PTEN inhibitors
IL316553A (en) 2022-05-15 2024-12-01 Nurexone Biologic Ltd Anti-pten rna interference oligonucleotides and uses thereof
CN116769037B (en) * 2022-09-14 2024-09-10 嘟乐士生物制药(河北)股份有限公司 Anti-aging composition containing collagen and application thereof in premature senility

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189308A1 (en) * 2008-03-17 2011-08-04 Asa Abeliovich Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
CA2724199C (en) * 2008-06-06 2016-07-26 Children's Medical Center Corporation Promoting axon regeneration in the adult cns through control of protein translation
JP5517078B2 (en) * 2009-04-09 2014-06-11 国立大学法人 宮崎大学 PTEN phosphorylation inhibitor or dephosphorylation agent
KR20100121710A (en) * 2009-04-30 2010-11-18 한국과학기술원 Method for prevention and treatment of retinal degeneration comprising activity regulation and administration of pten
EP2488637B1 (en) * 2009-10-16 2015-12-23 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
CA2854225A1 (en) * 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration

Also Published As

Publication number Publication date
CN105873942B (en) 2020-12-29
JP2017500283A (en) 2017-01-05
KR102405411B1 (en) 2022-06-08
JP6483115B2 (en) 2019-03-13
WO2015066701A1 (en) 2015-05-07
AU2014341899A1 (en) 2016-06-16
CN105873942A (en) 2016-08-17
EP3066116B1 (en) 2021-12-01
EP3066116A1 (en) 2016-09-14
US20160340396A1 (en) 2016-11-24
KR20160091347A (en) 2016-08-02
US20200270319A1 (en) 2020-08-27
AU2014341899B2 (en) 2018-12-13
CA2929483A1 (en) 2015-05-07
CA2929483C (en) 2021-11-23
EP3066116A4 (en) 2017-04-26
KR102086886B1 (en) 2020-03-10
US10584153B2 (en) 2020-03-10
KR20180095085A (en) 2018-08-24

Similar Documents

Publication Publication Date Title
ZA201505956B (en) Methods of treating melanoma
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
GB201317005D0 (en) Composition and methods of treatment
IL252547A0 (en) Treatment of multiple sclerosis with laquinimod
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201508515B (en) Treatment of coal
IL240014A0 (en) Treatment of multiple sclerosis with laquinimod
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
IL240763A0 (en) Halogenopyrazoles as inhibitors of therombin
IL241096B (en) Method of treatment
GB201607581D0 (en) Treatment of cancer
ZA201601626B (en) Treatment of gases
GB2525530B (en) Treatment of hard surfaces
AU2013901359A0 (en) Methods of Treatment
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201320653D0 (en) Treatment of plants
GB201306411D0 (en) Treatment of inflammatory conditions
AU2013902652A0 (en) Treatment of minerals
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
AU2013904712A0 (en) Method of Treatment
AU2013904170A0 (en) Method of treatment